Scarica l'app Stockscreener
13.04
0.23%
-0.03
Dopo l'orario di chiusura:
13.05
0.01
+0.08%
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Trading (TRDA) With Integrated Risk Controls - Stock Traders Daily
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
How the (TRDA) price action is used to our Advantage - Stock Traders Daily
Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says - Bloomberg Law
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025 - Nasdaq
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
(TRDA) Proactive Strategies - Stock Traders Daily
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
When (TRDA) Moves Investors should Listen - Stock Traders Daily
Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Acquires 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics : Corporate Presentation -January 15, 2025 at 04:41 pm EST - Marketscreener.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC - Defense World
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26% - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6%Here's Why - MarketBeat
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases - PR Newswire
Geode Capital Management LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC - MarketBeat
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Where are the Opportunities in (TRDA) - Stock Traders Daily
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
Charles Schwab Investment Management Inc. Has $2.97 Million Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):